HC Wainwright Issues Optimistic Forecast for Geron Earnings

Geron Corporation (NASDAQ:GERN) – Investment analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for shares of Geron in a report released on Wednesday, February 25th. HC Wainwright analyst E. Bodnar now forecasts that the biopharmaceutical company will post earnings of ($0.02) per share for the quarter, up from their prior forecast of ($0.03). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for Geron’s FY2026 earnings at ($0.02) EPS.

A number of other analysts have also weighed in on the stock. Needham & Company LLC lowered their price objective on shares of Geron from $5.00 to $4.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. UBS Group reaffirmed a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. TD Cowen reissued a “buy” rating on shares of Geron in a report on Thursday, January 29th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a research note on Wednesday, January 28th. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $2.17.

Geron Stock Performance

Shares of Geron stock opened at $1.65 on Friday. The firm has a market cap of $1.05 billion, a P/E ratio of -12.69 and a beta of 0.62. The company has a current ratio of 5.96, a quick ratio of 4.87 and a debt-to-equity ratio of 0.48. Geron has a 12 month low of $1.04 and a 12 month high of $2.01. The stock’s fifty day moving average price is $1.47 and its 200-day moving average price is $1.35.

Institutional Investors Weigh In On Geron

Several institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Geron by 2.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 392,534 shares of the biopharmaceutical company’s stock worth $627,000 after purchasing an additional 8,123 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Geron by 8.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,372,016 shares of the biopharmaceutical company’s stock worth $2,182,000 after purchasing an additional 104,840 shares in the last quarter. Savant Capital LLC grew its stake in Geron by 73.8% during the 2nd quarter. Savant Capital LLC now owns 26,074 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 11,074 shares during the last quarter. Nan Fung Trinity HK Ltd. acquired a new position in Geron during the 2nd quarter valued at about $1,937,000. Finally, Geode Capital Management LLC raised its stake in Geron by 4.3% in the second quarter. Geode Capital Management LLC now owns 14,152,038 shares of the biopharmaceutical company’s stock valued at $19,956,000 after buying an additional 584,444 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron News Summary

Here are the key news stories impacting Geron this week:

• Positive Sentiment: RYTELO commercial momentum — Geron reported $48.0M in Q4 RYTELO net product revenue and $183.6M for full‑year 2025, and reiterated 2026 RYTELO revenue guidance of $220–$240M; company says cash + marketable securities were roughly $401M at year‑end (supports near‑term runway). Geron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
• Positive Sentiment: Commercial traction & clinical catalysts — Q4 demand grew ~9% sequentially and ordering accounts rose by ~150 to ~1,300; company highlighted new peer‑reviewed publications and upcoming real‑world data and the IMpactMF interim analysis in H2 2026 that could expand uptake. Geron Corporation Q4 2025 Earnings Call Summary
• Neutral Sentiment: Earnings / transcript context — Q4 EPS matched the consensus at $(0.03) but revenue of ~$48.0M missed the ~$50.4M estimate; management reiterated operating expense guidance in a conference call. The transcript and call give more detail for investors tracking commercial cadence and cost assumptions. Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates
• Neutral Sentiment: Analyst modeling tweaks — HC Wainwright adjusted near‑term EPS estimates and trimmed a long‑range FY2028 view while keeping a Neutral rating, signaling mixed analyst conviction despite commercial progress. MarketBeat: HC Wainwright Estimates on GERN
• Negative Sentiment: Market and sell‑side skepticism — Some outlets and commentators flagged the revenue miss, cash decline vs. 2024 and the magnitude of operating expenses; Seeking Alpha reiterated/strengthened a sell stance after the Q4 release, contributing to intraday selling pressure. Geron: Why I’m Doubling Down On My ‘Sell’ Rating After Q4 Earnings
• Negative Sentiment: Cost and cash concerns — Full‑year operating expenses were ~$255M (within guidance) but restructuring charges (~$17M) and a larger full‑year net loss drove cash down from ~$503M at end‑2024 to ~$401M at end‑2025; investors may worry about burn/financing beyond 2026 if uptake or margins disappoint. QuiverQuant: Geron Reports $184M in RYTELO Revenue for 2025

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.